RGEN - Repligen Corporation Stock Price, News & Analysis

$33.91 -0.59 (-1.71 %)
(As of 11/23/2017 08:01 AM ET)
Previous Close$34.50
Today's Range$33.69 - $34.66
52-Week Range$28.48 - $46.81
Volume174,800 shs
Average Volume325,577 shs
Market Capitalization$1.50 billion
P/E Ratio59.48
Dividend YieldN/A
Beta1.05

About Repligen Corporation (NASDAQ:RGEN)

Repligen Corporation logoRepligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.


Industry, Sector and Symbol

Industry Specialty & Advanced Pharmaceuticals
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:RGEN
CUSIP75991610

Debt

Debt-to-Equity RatioN/A
Current Ratio1.95%
Quick Ratio1.63%

Price-To-Earnings

Trailing P/E Ratio59.48
Forward P/E Ratio55.59
P/E Growth2.25

Sales & Book Value

Annual Sales$104.54 million
Price / Sales14.13
Cash Flow$0.59 per share
Price / Cash57.01
Book Value$13.24 per share
Price / Book2.56

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS$0.59
Net Income$11.68 million
Net Margins16.93%
Return on Equity7.57%
Return on Assets5.19%

Miscellaneous

Employees236
Outstanding Shares43,560,000

Frequently Asked Questions for Repligen Corporation (NASDAQ:RGEN)

What is Repligen Corporation's stock symbol?

Repligen Corporation trades on the NASDAQ under the ticker symbol "RGEN."

How were Repligen Corporation's earnings last quarter?

Repligen Corporation (NASDAQ:RGEN) announced its quarterly earnings results on Thursday, November, 9th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.04. The biotechnology company earned $36.58 million during the quarter, compared to analyst estimates of $35.69 million. Repligen Corporation had a net margin of 16.93% and a return on equity of 7.57%. The firm's revenue was up 48.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.08 EPS. View Repligen Corporation's Earnings History.

When will Repligen Corporation make its next earnings announcement?

Repligen Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, February, 28th 2018. View Earnings Estimates for Repligen Corporation.

What guidance has Repligen Corporation issued on next quarter's earnings?

Repligen Corporation issued an update on its FY17 earnings guidance on Thursday, November, 9th. The company provided EPS guidance of $0.60-0.63 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.59. The company issued revenue guidance of $139-142 million, compared to the consensus revenue estimate of $140.72 million.

Where is Repligen Corporation's stock going? Where will Repligen Corporation's stock price be in 2017?

5 analysts have issued 12-month price targets for Repligen Corporation's shares. Their predictions range from $40.00 to $50.00. On average, they expect Repligen Corporation's stock price to reach $45.00 in the next twelve months. View Analyst Ratings for Repligen Corporation.

Who are some of Repligen Corporation's key competitors?

Who are Repligen Corporation's key executives?

Repligen Corporation's management team includes the folowing people:

  • Karen A. Dawes, Independent Chairperson of the Board (Age 64)
  • Tony John Hunt, President, Chief Executive Officer, Director (Age 53)
  • Jon K. Snodgres, Chief Financial Officer (Age 51)
  • Howard Benjamin Ph.D., Vice President - Business Development (Age 57)
  • Nicolas M. Barthelemy, Independent Director (Age 51)
  • Glenn L. Cooper M.D., Independent Director (Age 64)
  • John G. Cox, Independent Director (Age 54)
  • Glenn P. Muir, Independent Director (Age 58)
  • Thomas F. Ryan Jr., Independent Director (Age 75)

Who owns Repligen Corporation stock?

Repligen Corporation's stock is owned by many different of retail and institutional investors. Top institutional shareholders include TimesSquare Capital Management LLC (6.79%), Conestoga Capital Advisors LLC (3.89%), Stephens Investment Management Group LLC (2.70%), Dimensional Fund Advisors LP (1.93%), Macquarie Group Ltd. (2.21%) and Palisade Capital Management LLC NJ (1.76%). Company insiders that own Repligen Corporation stock include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen Corporation.

Who sold Repligen Corporation stock? Who is selling Repligen Corporation stock?

Repligen Corporation's stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, TimesSquare Capital Management LLC, Wells Fargo & Company MN, Russell Investments Group Ltd., Prudential Financial Inc., Pier Capital LLC, Schroder Investment Management Group and North Star Asset Management Inc.. Company insiders that have sold Repligen Corporation company stock in the last year include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes and Thomas F Ryan Jr. View Insider Buying and Selling for Repligen Corporation.

Who bought Repligen Corporation stock? Who is buying Repligen Corporation stock?

Repligen Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Conestoga Capital Advisors LLC, Mackenzie Financial Corp, Perceptive Advisors LLC, Assenagon Asset Management S.A., Kornitzer Capital Management Inc. KS, Stephens Investment Management Group LLC and American Century Companies Inc.. View Insider Buying and Selling for Repligen Corporation.

How do I buy Repligen Corporation stock?

Shares of Repligen Corporation can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Repligen Corporation's stock price today?

One share of Repligen Corporation stock can currently be purchased for approximately $33.91.

How big of a company is Repligen Corporation?

Repligen Corporation has a market capitalization of $1.50 billion and generates $104.54 million in revenue each year. The biotechnology company earns $11.68 million in net income (profit) each year or $0.59 on an earnings per share basis. Repligen Corporation employs 236 workers across the globe.

How can I contact Repligen Corporation?

Repligen Corporation's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at 781-250-0111 or via email at [email protected]


MarketBeat Community Rating for Repligen Corporation (RGEN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  98 (Vote Outperform)
Underperform Votes:  121 (Vote Underperform)
Total Votes:  219
MarketBeat's community ratings are surveys of what our community members think about Repligen Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Repligen Corporation (NASDAQ:RGEN)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 4 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $45.00 (32.70% upside)

Consensus Price Target History for Repligen Corporation (NASDAQ:RGEN)

Price Target History for Repligen Corporation (NASDAQ:RGEN)

Analysts' Ratings History for Repligen Corporation (NASDAQ:RGEN)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/13/2017CL KingInitiated CoverageBuy -> Buy$41.00N/AView Rating Details
10/19/2017Jefferies Group LLCReiterated RatingHold$40.00N/AView Rating Details
10/2/2017First AnalysisUpgradeEqual Weight -> Overweight$47.00MediumView Rating Details
9/26/2017StephensReiterated RatingOverweight$50.00HighView Rating Details
7/21/2017William BlairInitiated CoverageOutperform -> OutperformLowView Rating Details
6/23/2017Janney Montgomery ScottBoost Price Target$42.00 -> $47.00HighView Rating Details
2/22/2016Craig HallumInitiated CoverageBuyN/AView Rating Details
(Data available from 11/23/2015 forward)

Earnings

Earnings History and Estimates Chart for Repligen Corporation (NASDAQ:RGEN)

Earnings by Quarter for Repligen Corporation (NASDAQ:RGEN)

Earnings History by Quarter for Repligen Corporation (NASDAQ RGEN)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2018        
11/9/2017Q3 2017$0.11$0.15$35.69 million$36.58 millionViewN/AView Earnings Details
8/3/2017Q2 2017$0.15$0.20$31.72 million$32.40 millionViewListenView Earnings Details
5/4/20173/31/2017$0.13$0.15$29.28 million$30.59 millionViewListenView Earnings Details
2/22/2017Q416$0.07$0.08$24.05 million$25.60 millionViewListenView Earnings Details
11/3/2016Q316$0.08$0.08$24.39 million$24.70 millionViewN/AView Earnings Details
8/4/2016Q216$0.13$0.16$24.75 million$29.20 millionViewN/AView Earnings Details
5/5/2016Q116$0.10$0.12$22.54 million$25.10 millionViewN/AView Earnings Details
2/25/2016Q415$0.07$0.07$19.84 million$21.40 millionViewListenView Earnings Details
11/5/2015Q315$0.08$0.08$20.50 million$19.80 millionViewN/AView Earnings Details
8/6/2015Q215$0.08$0.11$20.05 million$21.50 millionViewN/AView Earnings Details
5/7/2015Q115$0.07$0.09$18.20 million$20.82 millionViewN/AView Earnings Details
3/13/2015Q414$0.04($0.01)$14.70 million$15.40 millionViewN/AView Earnings Details
11/6/2014Q314$0.04$0.04$15.60 million$15.30 millionViewN/AView Earnings Details
8/11/2014Q114$0.06$0.09$14.90 million$15.60 millionViewN/AView Earnings Details
5/8/2014Q1$0.07$0.13$15.14 million$16.33 millionViewListenView Earnings Details
3/6/2014Q413$0.14$0.10$15.88 million$10.40 millionViewListenView Earnings Details
11/7/2013Q313$0.13$0.18$16.27 million$18.80 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.10$0.14$15.97 million$17.50 millionViewListenView Earnings Details
5/2/2013Q1 2013$0.07$12.82 million$16.46 millionViewListenView Earnings Details
11/8/2012Q312$0.06$8.63 million$15.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Repligen Corporation (NASDAQ:RGEN)
2017 EPS Consensus Estimate: $0.54
2018 EPS Consensus Estimate: $0.70
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.13$0.13$0.13
Q2 20173$0.15$0.17$0.16
Q3 20174$0.09$0.15$0.13
Q4 20174$0.12$0.13$0.13
Q1 20183$0.16$0.17$0.16
Q2 20183$0.19$0.20$0.19
Q3 20183$0.15$0.20$0.18
Q4 20182$0.16$0.18$0.17
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Repligen Corporation (NASDAQ:RGEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Repligen Corporation (NASDAQ RGEN)

Insider Ownership Percentage: 1.50%
Institutional Ownership Percentage: 81.26%
Insider Trades by Quarter for Repligen Corporation (NASDAQ:RGEN)
Institutional Ownership by Quarter for Repligen Corporation (NASDAQ:RGEN)

Insider Trades by Quarter for Repligen Corporation (NASDAQ RGEN)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/21/2017Karen A DawesDirectorSell2,521$34.12$86,016.52View SEC Filing  
3/20/2017Howard BenjaminVPSell12,216$34.62$422,917.92View SEC Filing  
3/20/2017Thomas F Ryan JrDirectorSell4,000$34.83$139,320.00View SEC Filing  
3/17/2017Jon SnodgresCFOSell1,909$34.91$66,643.19View SEC Filing  
11/28/2016Anthony HuntCEOSell5,000$33.12$165,600.00View SEC Filing  
9/14/2016Thomas F Ryan JrDirectorSell2,700$32.58$87,966.00View SEC Filing  
6/30/2016Thomas F Ryan JrDirectorSell5,000$26.60$133,000.00View SEC Filing  
6/28/2016Thomas F Ryan JrDirectorSell10,000$24.59$245,900.00View SEC Filing  
5/11/2016Howard BenjaminVPSell2,889$26.72$77,194.08View SEC Filing  
6/9/2015Howard BenjaminVPSell35,000$38.14$1,334,900.00View SEC Filing  
5/11/2015Walter C HerlihyCEOSell104,569$37.94$3,967,347.86View SEC Filing  
5/8/2015Thomas F Ryan JrDirectorSell20,000$37.19$743,800.00View SEC Filing  
3/23/2015Walter C HerlihyCEOSell24,536$31.78$779,754.08View SEC Filing  
3/19/2015James R RuscheSVPSell14,650$33.30$487,845.00View SEC Filing  
3/19/2015Thomas F Ryan JrDirectorSell10,000$32.62$326,200.00View SEC Filing  
3/19/2015Walter C HerlihyCEOSell49,695$33.08$1,643,910.60View SEC Filing  
3/18/2015Howard BenjaminVPSell15,795$32.63$515,390.85View SEC Filing  
11/19/2014Walter C HerlihyCEOSell51,386$23.43$1,203,973.98View SEC Filing  
11/13/2014Thomas F Ryan JrDirectorSell10,000$23.81$238,100.00View SEC Filing  
11/11/2014Howard BenjaminVPSell30,000$23.56$706,800.00View SEC Filing  
11/10/2014Michael A GriffithDirectorSell23,342$22.90$534,531.80View SEC Filing  
8/13/2014Howard BenjaminVPSell40,000$20.34$813,600.00View SEC Filing  
6/27/2014Thomas F Ryan JrDirectorSell10,000$22.41$224,100.00View SEC Filing  
6/24/2014Thomas F Ryan JrDirectorSell10,000$21.78$217,800.00View SEC Filing  
6/11/2014Walter C HerlihyCEOSell60,335$20.11$1,213,336.85View SEC Filing  
6/9/2014James R RuscheSVPSell30,000$20.19$605,700.00View SEC Filing  
6/6/2014Daniel P WittSVPSell47,709$20.56$980,897.04View SEC Filing  
4/15/2014Daniel P WittSVPBuy10,000$3.05$30,500.00View SEC Filing  
8/8/2013James R RuscheSVPSell30,000$10.01$300,300.00View SEC Filing  
6/21/2013Karen A DawesDirectorBuy1,000$7.70$7,700.00View SEC Filing  
5/17/2013Thomas F Ryan JrDirectorSell21,000$8.97$188,370.00View SEC Filing  
5/15/2013Thomas F Ryan JrDirectorSell86,039$9.01$775,211.39View SEC Filing  
5/15/2013Walter C HerlihyCEOSell40,000$8.97$358,800.00View SEC Filing  
9/21/2012Glenn L Md CooperDirectorBuy10,000$6.09$60,900.00View SEC Filing  
8/16/2012Michael A GriffithDirectorBuy2,000$4.88$9,760.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Repligen Corporation (NASDAQ RGEN)

Source:
DateHeadline
First Analysis Research Analysts Lift Earnings Estimates for Repligen Corporation (RGEN)First Analysis Research Analysts Lift Earnings Estimates for Repligen Corporation (RGEN)
www.americanbankingnews.com - November 22 at 6:20 AM
TheStreet Downgrades Repligen Corporation (RGEN) to CTheStreet Downgrades Repligen Corporation (RGEN) to C
www.americanbankingnews.com - November 19 at 7:37 PM
Equities Analysts Offer Predictions for Repligen Corporations FY2017 Earnings (RGEN)Equities Analysts Offer Predictions for Repligen Corporation's FY2017 Earnings (RGEN)
www.americanbankingnews.com - November 17 at 8:08 PM
$0.13 Earnings Per Share Expected for Repligen Corporation (RGEN) This Quarter$0.13 Earnings Per Share Expected for Repligen Corporation (RGEN) This Quarter
www.americanbankingnews.com - November 16 at 9:28 AM
Repligen Corporation (RGEN) Given Average Recommendation of "Buy" by AnalystsRepligen Corporation (RGEN) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - November 13 at 2:12 AM
Edited Transcript of RGEN earnings conference call or presentation 9-Nov-17 1:30pm GMTEdited Transcript of RGEN earnings conference call or presentation 9-Nov-17 1:30pm GMT
finance.yahoo.com - November 12 at 12:16 PM
Repligen Corporation (RGEN) Announces  Earnings ResultsRepligen Corporation (RGEN) Announces Earnings Results
www.americanbankingnews.com - November 9 at 4:52 PM
RSI Alert: Repligen (RGEN) Now OversoldRSI Alert: Repligen (RGEN) Now Oversold
www.nasdaq.com - November 9 at 12:27 PM
Should You Sell Repligen Corporation (RGEN) Before Earnings?Should You Sell Repligen Corporation (RGEN) Before Earnings?
finance.yahoo.com - November 9 at 12:27 PM
Repligen Corporation to Host Earnings CallRepligen Corporation to Host Earnings Call
finance.yahoo.com - November 9 at 12:27 PM
Repligen Reports Third Quarter 2017 Financial ResultsRepligen Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 12:27 PM
Repligen tops Street 3Q forecastsRepligen tops Street 3Q forecasts
finance.yahoo.com - November 9 at 12:27 PM
Repligen Corporation (RGEN) Issues FY17 Earnings GuidanceRepligen Corporation (RGEN) Issues FY17 Earnings Guidance
www.americanbankingnews.com - November 9 at 9:22 AM
Repligen Extends Long Term Supply Agreement with Purolite for Protein A LigandsRepligen Extends Long Term Supply Agreement with Purolite for Protein A Ligands
finance.yahoo.com - November 7 at 9:33 AM
Repligen Corporation (RGEN) Set to Announce Quarterly Earnings on ThursdayRepligen Corporation (RGEN) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - November 2 at 4:38 AM
Purolite Selects Repligens Market-Leading OPUS® Pre-Packed Columns - PR Newswire (press release)Purolite Selects Repligen's Market-Leading OPUS® Pre-Packed Columns - PR Newswire (press release)
www.prnewswire.com - November 1 at 3:41 PM
Repligen to Report Third Quarter 2017 Financial ResultsRepligen to Report Third Quarter 2017 Financial Results
finance.yahoo.com - November 1 at 3:41 PM
ETFs with exposure to Repligen Corp. : November 1, 2017ETFs with exposure to Repligen Corp. : November 1, 2017
finance.yahoo.com - November 1 at 3:41 PM
Purolite Selects Repligens Market-Leading OPUS® Pre-Packed ColumnsPurolite Selects Repligen's Market-Leading OPUS® Pre-Packed Columns
finance.yahoo.com - November 1 at 8:04 AM
Stocks With Rising Relative Strength: RepligenStocks With Rising Relative Strength: Repligen
finance.yahoo.com - November 1 at 8:04 AM
Head to Head Contrast: Mallinckrodt PLC (MNK) & Repligen Corporation (RGEN)Head to Head Contrast: Mallinckrodt PLC (MNK) & Repligen Corporation (RGEN)
www.americanbankingnews.com - October 30 at 12:58 AM
Repligen Corporation (RGEN) Expected to Post Earnings of $0.11 Per ShareRepligen Corporation (RGEN) Expected to Post Earnings of $0.11 Per Share
www.americanbankingnews.com - October 27 at 3:06 AM
Head to Head Contrast: Macrocure (MCUR) versus Repligen Corporation (RGEN)Head to Head Contrast: Macrocure (MCUR) versus Repligen Corporation (RGEN)
www.americanbankingnews.com - October 26 at 5:35 PM
Repligen Corporation (RGEN) Set to Announce Quarterly Earnings on WednesdayRepligen Corporation (RGEN) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 25 at 7:49 AM
Repligen Corporation (RGEN) Rating Reiterated by Jefferies Group LLCRepligen Corporation (RGEN) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - October 22 at 9:44 PM
RGEN Crosses Above Key Moving Average LevelRGEN Crosses Above Key Moving Average Level
www.nasdaq.com - October 20 at 3:58 PM
ETFs with exposure to Repligen Corp. : October 20, 2017ETFs with exposure to Repligen Corp. : October 20, 2017
finance.yahoo.com - October 20 at 3:57 PM
Repligen Corporation (RGEN) Given Consensus Rating of "Buy" by BrokeragesRepligen Corporation (RGEN) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 19 at 2:34 AM
Contrasting Advanced Accelerator Applications (AAAP) and Repligen Corporation (RGEN)Contrasting Advanced Accelerator Applications (AAAP) and Repligen Corporation (RGEN)
www.americanbankingnews.com - October 18 at 4:24 PM
Critical Survey: Repligen Corporation (RGEN) versus TherapeuticsMD (TXMD)Critical Survey: Repligen Corporation (RGEN) versus TherapeuticsMD (TXMD)
www.americanbankingnews.com - October 15 at 9:00 AM
Financial Comparison: Mallinckrodt PLC (MNK) vs. Repligen Corporation (RGEN)Financial Comparison: Mallinckrodt PLC (MNK) vs. Repligen Corporation (RGEN)
www.americanbankingnews.com - October 12 at 4:24 PM
Repligen Corporation (RGEN) Cut to "Hold" at Zacks Investment ResearchRepligen Corporation (RGEN) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - October 11 at 10:18 AM
Head to Head Review: Advanced Accelerator Applications (AAAP) & Repligen Corporation (RGEN)Head to Head Review: Advanced Accelerator Applications (AAAP) & Repligen Corporation (RGEN)
www.americanbankingnews.com - October 11 at 12:30 AM
ETFs with exposure to Repligen Corp. : October 9, 2017ETFs with exposure to Repligen Corp. : October 9, 2017
finance.yahoo.com - October 10 at 6:23 AM
Repligen Corporation (RGEN) versus Its Peers Head-To-Head ReviewRepligen Corporation (RGEN) versus Its Peers Head-To-Head Review
www.americanbankingnews.com - October 9 at 4:12 PM
Repligen Corporation (RGEN) Upgraded to Buy at Zacks Investment ResearchRepligen Corporation (RGEN) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - October 8 at 11:40 AM
Critical Contrast: Assembly Biosciences (ASMB) & Repligen Corporation (RGEN)Critical Contrast: Assembly Biosciences (ASMB) & Repligen Corporation (RGEN)
www.americanbankingnews.com - October 8 at 10:38 AM
$0.11 EPS Expected for Repligen Corporation (RGEN) This Quarter$0.11 EPS Expected for Repligen Corporation (RGEN) This Quarter
www.americanbankingnews.com - October 8 at 12:20 AM
Repligen Corporation (RGEN) to Post FY2020 Earnings of $1.12 Per Share, Jefferies Group ForecastsRepligen Corporation (RGEN) to Post FY2020 Earnings of $1.12 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - October 4 at 4:50 PM
Rockwell Medical (RMTI) vs. Repligen Corporation (RGEN) Head-To-Head AnalysisRockwell Medical (RMTI) vs. Repligen Corporation (RGEN) Head-To-Head Analysis
www.americanbankingnews.com - September 28 at 8:30 PM
Relative Strength Alert For Repligen - NasdaqRelative Strength Alert For Repligen - Nasdaq
www.nasdaq.com - September 27 at 11:15 PM
Notable Two Hundred Day Moving Average Cross - RGENNotable Two Hundred Day Moving Average Cross - RGEN
www.nasdaq.com - September 27 at 6:13 PM
Repligen Corp. (RGEN) Tumbled To Over A 4-Month LowRepligen Corp. (RGEN) Tumbled To Over A 4-Month Low
www.rttnews.com - September 27 at 6:13 PM
Brokers Set Expectations for Repligen Corporations Q2 2018 Earnings (RGEN)Brokers Set Expectations for Repligen Corporation's Q2 2018 Earnings (RGEN)
www.americanbankingnews.com - September 27 at 12:44 PM
Repligen Corporation (RGEN) Stock Rating Reaffirmed by StephensRepligen Corporation (RGEN) Stock Rating Reaffirmed by Stephens
www.americanbankingnews.com - September 26 at 7:34 PM
Mid-Afternoon Market Update: Ascena Retail Climbs Following Strong Earnings; Axovant Sciences Shares PlungeMid-Afternoon Market Update: Ascena Retail Climbs Following Strong Earnings; Axovant Sciences Shares Plunge
feeds.benzinga.com - September 26 at 3:28 PM
William Blair Comments on Repligen Corporations Q1 2018 Earnings (RGEN)William Blair Comments on Repligen Corporation's Q1 2018 Earnings (RGEN)
www.americanbankingnews.com - September 26 at 10:26 AM
Repligen continues slide ahead of Investor Day; shares down 11% in a weekRepligen continues slide ahead of Investor Day; shares down 11% in a week
seekingalpha.com - September 26 at 9:55 AM
Repligen Corporation (RGEN) & Supernus Pharmaceuticals (SUPN) Head to Head AnalysisRepligen Corporation (RGEN) & Supernus Pharmaceuticals (SUPN) Head to Head Analysis
www.americanbankingnews.com - September 24 at 6:18 PM
Repligen Corporation (RGEN) Receives Consensus Rating of "Buy" from BrokeragesRepligen Corporation (RGEN) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - September 24 at 2:56 AM

Social Media

Financials

Chart

Repligen Corporation (NASDAQ RGEN) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.